— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected. — Revenues grew 62% to $94.6 million, vs. $88.4 million expected. — Research and development expenses were $62.6 million, compared to $53.1 million last year. — FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from […]
“— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected. — Revenues grew 62% to $94.6 million, vs. $88.4 million expected. — Research and development expenses were $62.6 million, compared to $53.1 million last year. — FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from […]
· October 30, 2019
— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.
— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.
— Research and development expenses were $62.6 million, compared to $53.1 million last year.
— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.
— ACAD shares fell 0.81% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
